#USA #New Orleans #ASH Meeting #Jubilant Therapeutics #JBI-802

Jubilant Therapeutics Unveils Promising Phase 1 Results for JBI-802

Jubilant Therapeutics, a biopharmaceutical company at the forefront of developing precision therapies for myeloproliferative neoplasms (MPNs), is set to present compelling clinical results for its innovative drug JBI-802 at the upcoming 68th American Society of Hematology (ASH) Annual Meeting, which will be held from December 12 to 15, 2026, in New Orleans and online.

Overview of JBI-802

JBI-802 is a groundbreaking oral medication that acts as a dual inhibitor targeting both LSD1 and HDAC6, which are integral components of the CoREST complex. This approach aims to effectively manage various disease processes associated with essential thrombocythemia (ET), polycythemia vera (PV), and related myelodysplastic/myeloproliferative neoplasms. The Phase 1/2 study has generated substantial excitement as it opens new avenues for treating patients who've encountered challenges with standard care therapies.

Key Findings and Presentation Details

The forthcoming oral presentation by Jubilant Therapeutics will highlight the Phase 1 results from an open-label, multicenter trial examining JBI-802's safety, tolerability, and preliminary efficacy. Notably, early data offers a promising glimpse into the drug's potential. For instance, all eight patients who commenced treatment at a dosage of 15 mg saw more than a 50% reduction in platelet counts or reached normalization within three weeks, marking a median response time of just 15 days. Moreover, those who achieved normalization maintained their platelet counts within normal limits for extended periods, suggesting durability in their response.

Out of the 11 patients with leukocytosis at the 15 mg dosage, seven experienced a complete hematologic response, indicating a significant impact on blood cell regulation. Importantly, no dose-limiting toxicities were observed at the low dosage levels used, supporting the drug's tolerability profile.

The oral session is planned for December 14, 2026, at 5:15 PM CT, and will be accompanied by a poster presentation later that evening from 6:00 to 8:00 PM CT, where additional efficacy, safety, and molecular insights will be shared.

Upcoming Live Event

Furthermore, Jubilant Therapeutics will host an event titled Advancing the Treatment of Essential Thrombocythemia: The JBI-802 Opportunity, on the same day, providing investors and analysts a deeper insight into the Phase 1 study results. This event will be streamed live, with a replay available on the company’s official website, showcasing their commitment to transparency and engagement with the broader medical and investment communities.

Future Directions

JBI-802's development aligns with Jubilant Therapeutics' mission to address significant unmet medical needs in hematology. The company aims to leverage its robust background in medicinal chemistry and clinical development to deliver innovative therapies that can meaningfully enhance patient outcomes. Their ongoing efforts also include the development of other compounds, such as JBI-3041, indicating a diverse pipeline dedicated to combating various conditions across the medical spectrum.

In summary, the presentation of JBI-802’s data at the ASH Annual Meeting represents a pivotal moment not only for Jubilant Therapeutics but for the treatment landscape of myeloproliferative neoplasms. As the hematology community gathers to discuss advancements and share knowledge, this data could set the stage for broader acceptance and utilization of JBI-802 in clinical practice. With such encouraging results, the anticipation for future developments surrounding this therapeutic option continues to grow.